The long-term goal of the proposed study is to alter cell surface glycans that mediate cell-cell interactions and enhance cancer metastasis. We have described several modified disaccharides that permeate cell membranes, prime oligosaccharide synthesis by acting as alternate substrates (decoys), and alter the expression of sialyl Lewis X (sLe x) on cell surface glycoconjugates, sLe x constitutes part of the carbohydrate ligand recognized by cell adhesion molecules belonging to the family of selectin receptors on platelets, leukocytes, and endothelial cells, sLe x-containing ligands expressed on many types of carcinomas interact with selectins on these cells. This interaction is thought to facilitate tumor cell metastasis from primary tumors by promoting platelet-tumor cell aggregates, which lodge in the microvasculature of distant organs and form micrometastases. Patient survival studies after surgical resection of tumors indicate higher mortality for patients whose tumors type positive for sLe x and related antigens. Thus, the development of pharmacological agents to inhibit sLe x on tumor cells could improve patient survival. The hypothesis driving this research is that it should be possible to pharmacologically alter Lewis antigen presentation on tumor cells using disaccharide decoys. The specific objective of this proposal is to develop disaccharide analogs and to examine their therapeutic value for blocking cancer metastasis in mouse models. Positive results emerging from these studies will encourage us to translate our findings in model systems to phased trials in human cancer patients. Our five year goals include the following specific aims:
Aim 1. Synthesize disaccharide analogs of GIcNAcbetaa1,3GaI-R. We will make a series of analogs of N-acetyl-D-glucosaminea1,3-D-galactose (GlcNAcbeta3Gal) in which the 3', 4' and 6'-hydroxyl groups are missing, fluorinated, thiolated, alkylated, or aminated as potential inhibitors of sLe x formation. Analogs will be conjugated to various hydrophobic aglycones to determine the most effective derivative for cellular uptake and inhibitory activity. Radioactive forms of the disaccharides will be made to study the biodistribution of the compounds in mice.
Aim 2. Determine inhibitory activity of disaccharide analogs. Preliminary results show that peracetylated 4-deoxy- GlcNbetaca3Galbeta-O-naphthalenemethanol reduces the expression of sLex. The mode of action of this and other analogs will be examined in human LS 180 colon carcinoma cells and murine Lewis lung carcinoma (LLC) cells. Priming of oligosaccharides on the glycosides, alteration of endogenous glycoconjugate biosynthesis, and inhibition of selectin-mediated cell adhesion in vitro will be examined. Enzyme assays will establish if the compounds act as inhibitors of a4galactosyltransferase(s) involved in the biosynthesis of sLe/x.
Aim 3. Examine the therapeutic efficacy of disaccharide analogs on tumor metastasis and inflammation. Active compounds will be formulated and tested as inhibitors of experimental and spontaneous metastasis of LS 180 human colon carcinoma cells and syngeneic murine Lewis lung carcinoma. Solid tumor formation and inflammatory reactions will be analyzed to confirm the selective inhibitory action of the analog on tumor metastasis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA112278-03
Application #
7169842
Study Section
Pathobiochemistry Study Section (PBC)
Program Officer
Fu, Yali
Project Start
2005-02-09
Project End
2009-12-31
Budget Start
2007-02-01
Budget End
2007-12-31
Support Year
3
Fiscal Year
2007
Total Cost
$306,588
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Alavi Naini, Seyedeh Maryam; Yanicostas, Constantin; Hassan-Abdi, Rahma et al. (2018) Surfen and oxalyl surfen decrease tau hyperphosphorylation and mitigate neuron deficits in vivo in a zebrafish model of tauopathy. Transl Neurodegener 7:6
Brown, Jillian R; Yang, Feng; Sinha, Anjana et al. (2009) Deoxygenated disaccharide analogs as specific inhibitors of beta1-4-galactosyltransferase 1 and selectin-mediated tumor metastasis. J Biol Chem 284:4952-9
Schuksz, Manuela; Fuster, Mark M; Brown, Jillian R et al. (2008) Surfen, a small molecule antagonist of heparan sulfate. Proc Natl Acad Sci U S A 105:13075-80
Brown, Jillian R; Crawford, Brett E; Esko, Jeffrey D (2007) Glycan antagonists and inhibitors: a fount for drug discovery. Crit Rev Biochem Mol Biol 42:481-515
Brown, Jillian R; Nishimura, Yoshio; Esko, Jeffrey D (2006) Synthesis and biological evaluation of gem-diamine 1-N-iminosugars related to L-iduronic acid as inhibitors of heparan sulfate 2-O-sulfotransferase. Bioorg Med Chem Lett 16:532-6
Brown, Jillian R; Fuster, Mark M; Li, Ruixia et al. (2006) A disaccharide-based inhibitor of glycosylation attenuates metastatic tumor cell dissemination. Clin Cancer Res 12:2894-901